^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EDIT-202

    i
    Other names: EDIT-202, iPSC NK Cells, EDIT 202, EDIT202
    Company:
    Bayer, Editas Medicine, Shoreline Biosci
    Drug class:
    NK cell stimulant
    Related drugs:
    3years
    Deletion of CISH and TGFβR2 in iPSC-Derived NK Cells Promotes High Cytotoxicity and Enhances In Vivo Tumor Killing (ASH 2021)
    NK cells are typically isolated from either cord blood or peripheral blood of healthy donors, but recent advances with induced pluripotent stem cells (iPSCs) allows a nearly unlimited supply of iPSC-derived natural killer cells (iNK)...Together, the increased overall effector function of TGF β R2 -/- / CISH -/- DKO human iNK cells support their development as a potent allogeneic cell-based medicine for cancer. This potential medicine is being investigated with other gene edits for future advancement to clinic.
    Preclinical
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    EDIT-202